All In Biotech

Free tool

FAERS Monitor: Tepmetko

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214096 or its brand name (Tepmetko, Tepotinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

691

Serious

489

71% of reports

Hospitalization

188

Death reported

163

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death114
  • oedema66
  • diarrhoea58
  • oedema peripheral58
  • fatigue56
  • renal impairment56
  • off label use55
  • nausea44
  • disease progression43
  • peripheral swelling39
  • decreased appetite27
  • blood creatinine increased24
  • dyspnoea20
  • constipation19
  • pleural effusion19

Reports by year received

View as table
YearReports
20204
202169
202281
2023183
202492
2025105
2026157

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,468 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
oedemaSignal6637.129.52,285
renal impairmentSignal5620.315.81,012
oedema peripheralSignal5814.511.3719
blood creatinine increasedSignal2411.27.6213
disease progressionSignal4311.18.3386
pleural effusionSignal199.56.1137
peripheral swellingSignal397.75.7223
deathSignal1144.03.4267
decreased appetiteSignal273.52.447
diarrhoeaSignal582.72.164
constipationSignal192.71.718
fatigueSignal562.21.736
off label use551.91.524
nausea441.71.312
dyspnoea201.10.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.